AG

agilon health, inc.

AGLHealthcareNASDAQ

Medical Care Facilities

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$5.93B
-2.1% YoY
Net Income
-$391.3M
-50.4% YoY
EBITDA
-$368.9M
-69.1% YoY
Free Cash Flow
-$145.7M

Scan Results

Daily timeframe
1 recent day hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Oct 20▼ RSI OverboughtRSI 70.8, above 70, stock may be overbought
Oct 15▼ RSI OverboughtRSI 73.0, above 70, stock may be overbought
About agilon health, inc.

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. At a $1.51B market cap, agilon health, inc. ranks as a small-cap company within healthcare. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month.

Where AGL stands vs its 150-day and 200-day moving averages

As of the October 20, 2026 close, AGL finished 15.66% above its 150-day moving average ($76.80) and 43.44% above its 200-day moving average ($61.93). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is AGL overbought or oversold?

At the October 20, 2026 close, AGL's RSI(14) was 70.8, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$1.51B
Fwd P/E37.99
EPS$-15.41
Beta3.00
52W Change+279.3%
Dividend Yield0.00%
ROE-78.9%
Analysis

The balance sheet looks solid with $185.6M in cash comfortably exceeding the $33.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$145.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -78.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $2.39B (2022) to $5.93B (2025), reflecting a 148% increase over the period.

With a beta above 1.5, AGL tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing AGL.

Links
More Healthcare stocks
Browse all stocks →
⚠Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms